We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum DNA Biomarkers Are Applicable to Cancers and Chronic Diseases.

By LabMedica International staff writers
Posted on 07 Sep 2010
Disease-related fragments of DNA that are released into the bloodstream by apoptotic cells can be screened and analyzed. More...


Disease-specific biomarkers based on DNA fragments are found in the bloodstream from damaged and dying (apoptotic) cells. These serum DNA biomarkers are applicable to diagnosing a wide range of cancers and other chronic diseases.

Chronix Biomedical (San Jose, CA, USA) has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany's first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, (Germany), where the company has research facilities.

The new system allows Chronix to screen and analyze 25-times more genomes each month far more cost-effectively than was possible with older methods. It has reduced the time needed to screen a genome by about 80%, while improving reproducibility of the results. The new system has already enhanced the performance of Chronix's initial tests for breast and prostate cancer, and it is expected to accelerate development and commercialization efforts across the board. Chronix has developed proprietary diagnostic databases and related information using algorithms they developed to detect, analyze and identify disease-related fragments of DNA that are released into the bloodstream by apoptotic cells. This apoptotic DNA originates from a limited number of chromosomal regions, or "hotspots," on the genome that are specific to each illness. By focusing on these genomic hotspots, the Chronix tests can reliably detect the presence of cancer without having first to isolate and analyze tumor cells, an important advantage.

Ekkehard Schütz, M.D., Ph.D., vice president of research at Chronix Biomedical, said, "Our proprietary technology has demonstrated excellent accuracy in the early detection of breast cancer and prostate cancer, and these new mass-sequencing capabilities will allow us to rapidly develop tests for cancer and other chronic diseases."

Related Links:
Chronix Biomedical
University of Göttingen


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.